Vigil Neuroscience, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Ivana Magovcevic-Liebisch
- Full Time Employees
- 69
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1 Broadway Watertown MA United States of America 02142
- IPO Date
- Jan 7, 2022
- CIK
- 0001827087
- Website
- vigilneuro.com
- Similar Companies
- Business
- Vigil Neuroscience, Inc. is a clinical-stage biotechnology company specializing in the development of novel therapeutics targeting microglial cells to treat neurodegenerative diseases. The company’s main products include iluzanebart, a therapeutic antibody in late-stage development for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), and VG-3927, an oral small molecule TREM2 agonist aimed at enhancing microglial function in Alzheimer's disease. Vigil develops precision-based therapies leveraging modern neuroscience drug development tools and collaborates with academic, pharmaceutical, and biotechnology partners. Headquartered in Cambridge, Massachusetts, the company operates primarily in the United States within the neurology and biotechnology sectors. In recent major developments, Vigil Neuroscience was acquired by Sanofi in August 2025 for approximately $470 million, marking a significant strategic shift. This acquisition adds Vigil's novel TREM2 agonist pipeline to Sanofi’s neurology portfolio, strengthening Sanofi’s early-stage pipeline in neurodegenerative disease treatments. Following positive Phase 1 clinical trial data demonstrating VG-3927’s safety and pharmacological effectiveness, Vigil initiated plans for a Phase 2 trial for Alzheimer's disease in the third quarter of 2025. Meanwhile, Vigil's IGNITE Phase 2 trial of iluzanebart in ALSP proceeded toward final analysis in the second quarter of 2025. Prior to the acquisition, Vigil secured a $40 million strategic investment from Sanofi in 2024 to fuel its research and development efforts in neurodegenerative diseases. Vigil Neuroscience’s pipeline focuses on TREM2-targeting therapies designed to restore microglial function and ameliorate neurodegeneration, addressing critical unmet needs in Alzheimer's disease and rare neuroangiopathies. The company’s strategy involves advancing genetically credentialed, small molecule and antibody therapeutic candidates through clinical development to potentially transformative treatments. The acquisition by Sanofi is expected to accelerate the development and broaden the global reach of these innovative therapies. Vigil Neuroscience was founded in 2018 and is positioned at the forefront of microglia-focused neuroscience therapeutics research and development.
VIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil Neuroscience, Inc. - VIGL
Wall Street Analysts See a 26.1% Upside in Vigil Neuroscience (VIGL): Can the Stock Really Move This High?
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HURA and VIGL on Behalf of Shareholders
Wall Street Analysts Think Vigil Neuroscience (VIGL) Could Surge 26.9%: Read This Before Placing a Bet
VIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors to Contact the Firm
Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP
Should You Buy Vigil Neuroscience, Inc. (VIGL) After Golden Cross?
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Vigil Neuroscience, Inc. (NASDAQ: VIGL)
Wall Street Analysts Believe Vigil Neuroscience (VIGL) Could Rally 86.68%: Here's is How to Trade
VIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil Neuroscience, Inc. - VIGL
Shareholder Alert: The Ademi Firm Investigates Whether Vigil Neuroscience Inc. Is Obtaining a Fair Price for Its Public Shareholders
VIGL Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Vigil Neuroscience, Inc. is Fair to Shareholders
Sanofi to Buy Vigil Neuroscience for About $470 Million
Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi
Sanofi to acquire Vigil Neuroscience in $470 million deal
Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates
Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference
Vigil Neuroscience (VIGL) Upgraded to Buy: Here's What You Should Know
Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Updates
Vigil Neuroscience to Present at the Stifel 2025 Virtual CNS Forum